| A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With α- or β-Non-Transfusion-Dependent Thalassemia (NCT07517133) | Agios Pharmaceuticals, Inc. | 2026-09-01 |
| A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT) (NCT07506863) | Agios Pharmaceuticals, Inc. | 2026-09-01 |
| A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD) (NCT07656415) | Agios Pharmaceuticals, Inc. | 2026-07-21 |
| A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-181 in Subjects With Phenylketonuria (NCT07241234) | Agios Pharmaceuticals, Inc. | 2026-04-17 |
| A Study of Mitapivat in Participants With Sickle Cell Disease and Nephropathy (NCT06286046) | Agios Pharmaceuticals, Inc. | 2026-03-01 |
| A Study to Determine the Safety and Tolerability of AG-236 and How it is Absorbed, Broken Down, and Eliminated From the Body in Healthy Participants (NCT07075640) | Agios Pharmaceuticals, Inc. | 2025-07-07 |
| A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD) (NCT06924970) | Agios Pharmaceuticals, Inc. | 2025-05-01 |
| A Study to Determine How Tebapivat is Absorbed, Broken Down, and Removed From the Body and the Extent to Which Tebapivat is Made Available in the Body in Healthy Participants (NCT06745271) | Agios Pharmaceuticals, Inc. | 2024-12-20 |
| Study of How Mitapivat Affects Midazolam Blood Levels in Healthy Participants (NCT06648824) | Agios Pharmaceuticals, Inc. | 2024-10-17 |
| Single and Multiple Ascending Dose Study and Food Effect Study for AG181 (NCT06286033) | Agios Pharmaceuticals, Inc. | 2024-02-20 |
| A Study to Provide Access to Mitapivat for Participants Who Previously Participated in an Agios-Sponsored Mitapivat Study (NCT05777993) | Agios Pharmaceuticals, Inc. | 2023-07-06 |
| A Pharmacokinetic Study of Mitapivat in Participants With Moderate Hepatic Impairment Compared to Matched Healthy Control Participants With Normal Hepatic Function (NCT05610657) | Agios Pharmaceuticals, Inc. | 2023-01-10 |
| A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS) (NCT05490446) | Agios Pharmaceuticals, Inc. | 2022-11-07 |
| A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Not Regularly Transfused, Followed by a 5-Year Extension Period (NCT05175105) | Agios Pharmaceuticals, Inc. | 2022-06-06 |
| A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP) (NCT05031780) | Agios Pharmaceuticals, Inc. | 2022-02-11 |
| A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-NTDT) (NCT04770753) | Agios Pharmaceuticals, Inc. | 2021-12-20 |
| A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT) (NCT04770779) | Agios Pharmaceuticals, Inc. | 2021-11-30 |
| Pyruvate Kinase Deficiency Global Longitudinal Registry Substudy of Protocol AG348-C-008 (NCT04995315) | Agios Pharmaceuticals, Inc. | 2021-07-02 |
| Pyruvate Kinase (PK) Deficiency Global Longitudinal Registry: Patient-Reported Outcomes (PRO) (NCT04964323) | Agios Pharmaceuticals, Inc. | 2021-07-02 |
| A Study to Assess the Relative Bioavailability and Effect of Food on the Coated Granule Formulation of Mitapivat in Healthy Participants (NCT04565678) | Agios Pharmaceuticals, Inc. | 2020-09-21 |
| A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers and in Participants With Sickle Cell Disease (NCT04536792) | Agios Pharmaceuticals, Inc. | 2020-07-10 |
| A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Mitapivat (AG-348) in Healthy Adult Participants (NCT04472832) | Agios Pharmaceuticals, Inc. | 2020-06-17 |
| A Study to Evaluate AG-881 in Healthy Japanese and Non-Asian Participants (NCT04145128) | Agios Pharmaceuticals, Inc. | 2019-10-02 |
| A Study to Compare the Relative Bioavailability of Two AG-881 Formulations and Evaluate the Effect of Food and Omeprazole on the Pharmacokinetics of AG-881 (NCT04128787) | Agios Pharmaceuticals, Inc. | 2019-09-30 |
| A Study to Evaluate the Effect of AG-881 on the Pharmacokinetics of a Single Dose of Lamotrigine in Healthy Adults (NCT04015687) | Agios Pharmaceuticals, Inc. | 2019-07-15 |
| Study to Evaluate the Effect of Multiple Doses of Itraconazole and Rifampin on the Single-Dose Pharmacokinetics of Mitapivat Sulfate (AG-348) in Healthy Adult Participants (NCT03991312) | Agios Pharmaceuticals, Inc. | 2019-06-20 |
| A Study of AG-636 in the Treatment of Subjects With Advanced Lymphoma (NCT03834584) | Agios Pharmaceuticals, Inc. | 2019-05-24 |
| A Safety and Pharmacokinetic Study of AG-881 in Healthy Male Participants Following Administration of a Single Oral Dose of [14C] AG-881 and Concomitant Intravenous Microdose of [13C315N3] AG-881 (NCT03960502) | Agios Pharmaceuticals, Inc. | 2019-05-16 |
| Extension Study of AG-348 in Adult Participants With Pyruvate Kinase Deficiency Previously Enrolled in AG-348-006 or AG348-C-007 (NCT03853798) | Agios Pharmaceuticals, Inc. | 2019-03-21 |
| A Study to Determine the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AG-348 in Adult Participants With Non-transfusion-dependent Thalassemia (NCT03692052) | Agios Pharmaceuticals, Inc. | 2019-03-20 |
| A Study to Evaluate Efficacy and Safety of AG-348 in Not Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD) (NCT03548220) | Agios Pharmaceuticals, Inc. | 2018-08-09 |
| A Study Evaluating the Efficacy and Safety of AG-348 in Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD) (NCT03559699) | Agios Pharmaceuticals, Inc. | 2018-06-26 |
| A Study to Evaluate the Absorption, Distribution, Metabolism, Excretion and Absolute Bioavailability of AG-348 in Healthy Male Participants Following Administration of a Single Oral Dose of [14C]AG-348 and Concomitant Single Intravenous Microdose of [13C6]AG-348 (NCT03703505) | Agios Pharmaceuticals, Inc. | 2018-05-24 |
| Pyruvate Kinase Deficiency Global Longitudinal Registry (NCT03481738) | Agios Pharmaceuticals, Inc. | 2018-04-23 |
| Pre-Screening Study to Identify MTAP Loss in Advanced Solid Tumors or Lymphoma (NCT03361358) | Agios Pharmaceuticals, Inc. | 2018-03-01 |
| Study to Evaluate the Relative Bioavailability and Safety of the AG-348 Tablet and Capsule Formulations in Healthy Adults (NCT03397329) | Agios Pharmaceuticals, Inc. | 2017-10-03 |